<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01071018</url>
  </required_header>
  <id_info>
    <org_study_id>2206-007</org_study_id>
    <secondary_id>2010_509</secondary_id>
    <nct_id>NCT01071018</nct_id>
  </id_info>
  <brief_title>A Study of MK2206 in Locally Advanced or Metastatic Solid Tumors (2206-007)</brief_title>
  <official_title>A Phase I Study of MK2206 in Patients With Locally Advanced or Metastatic Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to evaluate the safety and tolerability, pharmacokinetics,
      pharmacodynamics and anti-tumor activity of MK2206 when administered with Every Other Day
      (QOD) and Once Weekly (QW) dosing schedules.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2010</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Characterize safety and tolerability of MK2206 by monitoring incidence of protocol-defined dose limiting toxicities (DLTs)</measure>
    <time_frame>Day 1 - Day 28 (Cycle 1)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess pharmacokinetic (PK) profile of MK2206 by determining parameters: AUC, Cmax, and Tmax</measure>
    <time_frame>Day 1 - Day 28 (Cycle 1)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Solid Tumors</condition>
  <arm_group>
    <arm_group_label>QOD Schedule</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>QOD Schedule, MK2206 every other day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>QW Schedule</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>QW Schedule, MK2206 once weekly</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK2206 every other day</intervention_name>
    <description>Dose escalation study: MK2206 will be administered as an oral formulation in rising dose levels of 45 mg and 60 mg, once daily every other day in repeating 4 week cycles.</description>
    <arm_group_label>QOD Schedule</arm_group_label>
    <other_name>MK2206</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK2206 once weekly</intervention_name>
    <description>Dose escalation study: MK2206 will be administered as an oral formulation in rising dose levels of 135 mg and 200 mg, once weekly in repeating 4 week cycles.</description>
    <arm_group_label>QW Schedule</arm_group_label>
    <other_name>MK2206</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient must have confirmed locally advanced or metastatic solid tumors that have
             failed to respond to standard therapy, have gotten worse or have come back after
             existing therapy

          -  Has adequate organ function

          -  Is ECOG Performance Scale 0-1

          -  Has a negative urine pregnancy test if patient is female

          -  Is able to swallow capsules and has no surgical or bodily condition that will prevent
             the patient from swallowing and absorbing oral medications on an ongoing basis

        Exclusion Criteria:

          -  Patient has had chemotherapy, radiotherapy, biological therapy or surgery within 4
             weeks of starting the study and has not recovered from adverse events caused by the
             treatment

          -  Is currently participating or has participated in a study with an investigational
             compound or device within 28 days

          -  Has a primary central nervous system tumor

          -  Has a history or current evidence of heart disease, slow heart rate or untreated high
             blood pressure

          -  Is a known diabetic who is taking insulin or oral antidiabetic therapy

          -  Is pregnant or breastfeeding or planning to become pregnant during the study

          -  Is positive HIV antibody, HBs antigen or HCV antibody
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Japan</country>
  </removed_countries>
  <reference>
    <citation>Doi T, Tamura K, Tanabe Y, Yonemori K, Yoshino T, Fuse N, Kodaira M, Bando H, Noguchi K, Shimamoto T, Ohtsu A. Phase 1 pharmacokinetic study of the oral pan-AKT inhibitor MK-2206 in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol. 2015 Aug;76(2):409-16. doi: 10.1007/s00280-015-2810-z. Epub 2015 Jun 24.</citation>
    <PMID>26104654</PMID>
  </reference>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 17, 2010</study_first_submitted>
  <study_first_submitted_qc>February 17, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 18, 2010</study_first_posted>
  <last_update_submitted>September 4, 2015</last_update_submitted>
  <last_update_submitted_qc>September 4, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 7, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>locally advanced or metastatic solid tumors</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

